Literature DB >> 25965360

Toxicity patterns with immunomodulating antibodies and their combinations.

John B A G Haanen1, Hans van Thienen2, Christian U Blank2.   

Abstract

Immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), but also LAG-3 and TIM-3, are involved in regulation of peripheral tolerance in order to prevent autoimmunity. Blocking of these cell surface proteins by antibodies has resulted in remarkable anti-tumor immunity; however this immunity is accompanied by immune-related adverse reactions (irAEs), resembling autoimmune diseases. Hence, treatment with immunosuppressive drugs is highly effective and resolves the symptoms caused by these adverse events rapidly. In this review, toxicity patterns observed with immune checkpoint blockade are described for single-agent and combination treatments.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25965360     DOI: 10.1053/j.seminoncol.2015.02.011

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  22 in total

1.  SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Authors:  Jungsun Park; Amjad H Talukder; Seon A Lim; Kwanghee Kim; Ke Pan; Brenda Melendez; Sherille D Bradley; Kyle R Jackson; Jahan S Khalili; Junmei Wang; Caitlin Creasy; Bih-Fang Pan; Scott E Woodman; Chantale Bernatchez; David Hawke; Patrick Hwu; Kyung-Mi Lee; Jason Roszik; Gregory Lizée; Cassian Yee
Journal:  Cancer Immunol Res       Date:  2017-06-19       Impact factor: 11.151

2.  Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis.

Authors:  Hajir Ibraheim; Michael Green; Sophie Papa; Nick Powell
Journal:  BMJ Case Rep       Date:  2019-04-03

3.  At the Checkpoint: Lung CD8(+) T Cells, Respiratory Viruses, and Chronic Obstructive Pulmonary Disease.

Authors:  Jeffrey L Curtis
Journal:  Am J Respir Crit Care Med       Date:  2016-03-15       Impact factor: 21.405

Review 4.  The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics.

Authors:  Jessica Menis; Saskia Litière; Konstantinos Tryfonidis; Vassilis Golfinopoulos
Journal:  Ann Transl Med       Date:  2016-07

5.  A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema.

Authors:  Jason M Redman; Logan P Rhea; Lisa Cordes; Helen Owens; Ravi A Madan; Marijo Bilusic; James L Gulley; Jung-Min Lee; William L Dahut; Fatima Karzai
Journal:  Clin Genitourin Cancer       Date:  2019-02-14       Impact factor: 2.872

Review 6.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Authors:  J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

7.  Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.

Authors:  Scott C Bresler; Le Min; Scott J Rodig; Andrew C Walls; Shuyun Xu; Songmei Geng; F Stephen Hodi; George F Murphy; Christine G Lian
Journal:  Lab Invest       Date:  2016-12-05       Impact factor: 5.662

8.  Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung.

Authors:  Isha Verma; Anar Modi; Hemantkumar Tripathi; Abhinav Agrawal
Journal:  BMJ Case Rep       Date:  2016-01-05

Review 9.  Nivolumab in combination with ipilimumab for the treatment of melanoma.

Authors:  Rajasekharan Somasundaram; Meenhard Herlyn
Journal:  Expert Rev Anticancer Ther       Date:  2015       Impact factor: 4.512

Review 10.  Checkpoint Inhibitors, Palliative Care, or Hospice.

Authors:  Mellar P Davis; Rajiv Panikkar
Journal:  Curr Oncol Rep       Date:  2018-01-19       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.